Topic: Pharmaceuticals

CAT upholds pay-for-delay decision but trims penalties

The UK’s specialist competition tribunal has confirmed that GlaxoSmithKline and three generic drugmakers broke competition rules by entering into pay-for-delay agreements for the antidepressant drug paroxetine – but slashed the original fines by £27 million.

10 May 2021

Congress sets sights on pharma legislation

A bipartisan group of lawmakers introduced a bundle of bills on Thursday designed to empower the Federal Trade Commission to stop branded pharmaceutical companies from delaying market entry of generic competition.

30 April 2021

China hits pharma company with major fine

China’s competition watchdog has fined a major pharmaceutical group about €97.6 million for fixing the resale price of multiple drugs over a four year period.

28 April 2021

Top Swiss court rules that recommended retail prices are anticompetitive

Switzerland’s highest court has ruled that Pfizer’s recommended price-lists for an erectile dysfunction drug restricted competition, in a decision that local competition lawyers say creates uncertainty about the legality of recommended resale prices.

26 April 2021

Gail Levine: the GCR exit interview

Gail Levine – the last of the antitrust holdovers from the Joseph Simons-era at the Federal Trade Commission – departed earlier this month after helping the next administration get situated. The former deputy director of the FTC’s bureau of competition spoke with GCR USA about the need for additional funding and her experience overseeing the agency’s technology and pharmaceutical shops during a pandemic.

26 April 2021

French court declines to block Illumina/Grail merger referral to EU

France's Council of State has rejected an application from Illumina to suspend the national competition authority's referral of its acquisition of Grail to the European Commission, which is the first time the authority has referred a below-threshold deal to the EU agency.

09 April 2021

Austrian enforcer settles predatory pricing probe into Merck

Austria's Federal Competition Authority has accepted commitments from pharmaceutical company Merck Sharp & Dohme's local subsidiary to stop charging predatory prices for a brain tumour drug.

06 April 2021

First EU pay-for-delay fines survive ECJ challenge

In a highly-anticipated ruling, the European Court of Justice has confirmed the European Commission’s first-ever pay-for-delay decision fining Lundbeck and five generic drugmakers a combined €146 million.

25 March 2021

Italian court turns to ECJ again in eye drug misinformation case

Italy’s supreme administrative court has asked the European Court of Justice to weigh-in for a second time on a challenge brought by Roche and Novartis against a €180.5 million collusion fine levied against them by the country’s competition enforcer.

23 March 2021

FTC seeks new approach for reviewing pharmaceutical mergers

The Federal Trade Commission has launched a working group of international enforcers looking for new ways to analyse and challenge pharmaceutical mergers.

17 March 2021

Get unlimited access to all Global Competition Review content